Antirheumatic drugs (DMARDs) are capable of controlling synovial inflammation and there are advantages and disadvantages of DMARD therapy with agents such as methotrexate, leflunomide, sulfasalazine, injectable gold and (hydroxy)chloroquine with biological therapies, and with the new era of kinase inhibitors. Pub Med Immunotherapy. 2013 Sep;5(9):955-74. (Also see: Rheumatoid Arthritis)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.